Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I–deficient breast cancer cells
Authors:
- 1 December 2019
- journal article
- research article
- Published by Springer Nature in Immunologic Research
- Vol. 67 (6) , 497-504
Abstract
Breast cancer is the most dominant cancer in women and the second most frequent cancer in the general population worldwide. NLRC5 critically transactivates MHC class I (classically HLA-ABC in human) which is crucial for cancer immunosurveillance. But the expressional and functional impairments of NLRC5 have been found in many cancers as a major mechanism of immune evasion. Promotion of NLRC5 with the enhancement of MHC class I contributes to cancer immunotherapy and counteraction against cancer immune evasion. In many cancers, IFN-γ promotes the expression of MHC class I involving NLRC5; however, it is unclear in breast cancer cells. In this study, qRT-PCR, western blot, and flow cytometry were used to detect the mRNAs and proteins of NLRC5, β2m, and HLA-ABC in MHC class I–deficient human SKBR3 breast cancer cells after IFN-γ treatment. It was shown that the relative levels of NLRC5 mRNA, β2m mRNA, and HLA-ABC α heavy chain mRNA, in concentrations of 50 U/ml and 100 U/ml IFN-γ groups, were statistically increased (p < 0.05) with dose dependent tendency compared with the control group. The protein levels of NLRC5 and β2m in concentrations of 50 U/ml and 100 U/ml IFN-γ groups, HLA-ABC (positive rates) in different concentrations of IFN-γ groups, were statistically increased (p < 0.05), with dose dependent tendency for NLRC5 and HLA-ABC, compared with the control group. Promotion of NLRC5 by IFN-γ with upregulation of MHC class I (HLA-ABC) in SKBR3 breast cancer cells, suggesting the contribution to counteracting cancer evasion from immunosurveillance and benefiting cancer immunotherapy.Keywords
This publication has 67 references indexed in Scilit:
- Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancerProceedings of the National Academy of Sciences, 2013
- Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expressionOncoImmunology, 2012
- Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient miceCell Research, 2012
- A Role for the Human Nucleotide-binding Domain, Leucine-rich Repeat-containing Family Member NLRC5 in Antiviral ResponsesJournal of Biological Chemistry, 2010
- NLRC5 Limits the Activation of Inflammatory PathwaysThe Journal of Immunology, 2010
- NLR family member NLRC5 is a transcriptional regulator of MHC class I genesProceedings of the National Academy of Sciences, 2010
- Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinomaBritish Journal of Cancer, 2010
- NLRC5 Negatively Regulates the NF-κB and Type I Interferon Signaling PathwaysCell, 2010
- Killing tumor cells through their surface β2‐microglobulin or major histocompatibility complex class I moleculesCancer, 2010
- The Nucleotide-Binding Oligomerization Domain-Like Receptor NLRC5 Is Involved in IFN-Dependent Antiviral Immune ResponsesThe Journal of Immunology, 2010